Research Paper Volume 13, Issue 11 pp 15413—15432

Sex-related differences in the efficacy of immune checkpoint inhibitors in malignancy: a systematic review and meta-analysis

Progression-free survival hazard ratio in female patients in the immune checkpoint inhibitor group compared with the control group.

Figure 4. Progression-free survival hazard ratio in female patients in the immune checkpoint inhibitor group compared with the control group.